Omni Health, Inc., Reports $1.4M Gross Income for

MIAMI, FL--(Marketwired - Mar 9, 2017) - Omni Health, Inc., (OTC PINK: OMHE), a cannabis and biotech pharmaceutical company specializing in health and wellness products utilizing cannabis and biotech engineering, announced today its third quarter results for fiscal year 2017, ending January 31, 2016. OMHE recorded $1.4M gross income, bringing its year to date total to $3.2M in gross income. The third quarter results bring OMHE's net profit for the fiscal year to $915K.

OMHE Chief Executive Officer, Andrey Soloviev, stated, "We are pleased with the financial results considering it just incorporated the pharmacy revenue of OMHE, but OMHE is looking to broaden the scope of revenue through some strategic partnerships and opportunities. OMHE is looking to expand into cannabis and biotech, developing anti-aging creams and lotions."

About Omni Health, Inc.

Headquartered in Miami, Florida, Omni Health Inc., operates a pharmacy operation in Miami, Florida, Malecon Pharmacy. Malecon Pharmacy, a 40 year specialty pharmacy provider located in Miami, Florida currently transitioning into global health and wellness company providing healthcare products, pharmacy operations, prescription drugs, and other services and products in the skin care and anti-aging industry.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.